Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer.
Lu YS, Bin Mohd Mahidin EI, Azim H, Eralp Y, Yap YS, Im SA, Rihani J, Gokmen E, El Bastawisy A, Karadurmus N, Lim YN, Lim CS, Duc LT, Chung WP, Babu KG, Penkov K, Bowles J, Alfaro TD, Wu J, Gao M, Slimane K, El Saghir NS.
Lu YS, et al. Among authors: lim cs.
J Clin Oncol. 2024 May 21:JCO2400144. doi: 10.1200/JCO.24.00144. Online ahead of print.
J Clin Oncol. 2024.
PMID: 38771995